Compare · AKUS vs STOK
AKUS vs STOK
Side-by-side comparison of Akouos Inc. (AKUS) and Stoke Therapeutics Inc. (STOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- AKUS operates in Consumer Discretionary, while STOK operates in Health Care - the two are in different parts of the market.
- STOK is the larger of the two at $1.59B, about 8.1x AKUS ($197.0M).
- STOK has hit the wire 7 times in the past 4 weeks while AKUS has been quiet.
- STOK has more recent analyst coverage (18 ratings vs 1 for AKUS).
- Company
- Akouos Inc.
- Stoke Therapeutics Inc.
- Price
- -
- -
- Market cap
- $197.0M
- $1.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 0
- 7
- Recent ratings
- 1
- 18
Akouos Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Stoke Therapeutics Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest AKUS
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form 15-12G filed by Akouos Inc.
- SEC Form EFFECT filed by Akouos Inc.
- SEC Form 4 filed by Walker Paul Edward (tax withholding)
- SEC Form 4 filed by Sonsini Peter W. (tax withholding)
- SEC Form 4 filed by Sandell Scott D to satisfy withholding tax
- SEC Form 4 filed by Mathers Edward T (tax withholding)
Latest STOK
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
- Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
- Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $16,509 worth of shares (627 units at $26.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 20,598 units (SEC Form 4)
- CHIEF MEDICAL OFFICER Ticho Barry sold $27,494 worth of shares (1,051 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 19,059 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Stoke Therapeutics Inc.
- SEC Form 4 filed by Stoke Therapeutics Inc.
- SEC Form 3 filed by new insider Cumbo Alexander
- SEC Form 8-K filed by Stoke Therapeutics Inc.